{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:36:43Z","timestamp":1792460203686,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":1514,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM062882"],"award-info":[{"award-number":["GM062882"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["20160601"],"award-info":[{"award-number":["20160601"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s13311-019-00731-6","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T15:08:44Z","timestamp":1555600124000},"page":"635-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases"],"prefix":"10.1016","volume":"16","author":[{"given":"Alexey M.","family":"Petrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-6232","authenticated-orcid":false,"given":"Irina A.","family":"Pikuleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-019-00731-6_bib1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","article-title":"Cholesterol metabolism in the brain","volume":"12","author":"Dietschy","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"10.1007\/s13311-019-00731-6_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/BC.2009.035","article-title":"Central nervous system: cholesterol turnover, brain development and neurodegeneration","volume":"390","author":"Dietschy","year":"2009","journal-title":"Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.plipres.2011.06.002","article-title":"Cholesterol metabolism in neurons and astrocytes","volume":"50","author":"Pfrieger","year":"2011","journal-title":"Prog Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1086\/323473","article-title":"Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis","volume":"69","author":"Waterham","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-019-00731-6_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/301982","article-title":"Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene","volume":"63","author":"Waterham","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-019-00731-6_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2006.10.030","article-title":"Molecular anatomy of a trafficking organelle","volume":"127","author":"Takamori","year":"2006","journal-title":"Cell"},{"key":"10.1007\/s13311-019-00731-6_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/cne.903390307","article-title":"Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain","volume":"339","author":"Pasinetti","year":"1994","journal-title":"J Comp Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-0186(01)00049-3","article-title":"Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice","volume":"39","author":"DeMattos","year":"2001","journal-title":"Neurochem Int"},{"key":"10.1007\/s13311-019-00731-6_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/clp.10.37","article-title":"Apolipoproteins in the brain: implications for neurological and psychiatric disorders","volume":"51","author":"Elliott","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1007\/s13311-019-00731-6_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fnmol.2017.00382","article-title":"Intracellular Cholesterol Trafficking and Impact in Neurodegeneration","volume":"10","author":"Arenas","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind a barrier","volume":"24","author":"Bjorkhem","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1007\/s13311-019-00731-6_bib13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaneurol.2014.2011","article-title":"Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function","volume":"71","author":"Mak","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib14","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1194\/jlr.R047837","article-title":"Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin","volume":"55","author":"Vance","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib15","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1016\/S0021-9258(18)83172-6","article-title":"Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme","volume":"264","author":"Andersson","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1286.007","article-title":"Neurosteroid biosynthesis in the human brain and its clinical implications","volume":"1007","author":"Stoffel-Wagner","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-019-00731-6_bib17","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.96.13.7238","article-title":"cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain","volume":"96","author":"Lund","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib18","doi-asserted-by":"crossref","first-page":"22980","DOI":"10.1074\/jbc.M303415200","article-title":"Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover","volume":"278","author":"Lund","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib19","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0022-2275(20)32188-X","article-title":"Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation","volume":"39","author":"Bjorkhem","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib20","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1073\/pnas.93.18.9799","article-title":"Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation","volume":"93","author":"Lutjohann","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib21","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M200293-JLR200","article-title":"On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function","volume":"43","author":"Meaney","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/02713680701231857","article-title":"Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in neurons of the neural retina","volume":"32","author":"Bretillon","year":"2007","journal-title":"Curr Eye Res"},{"key":"10.1007\/s13311-019-00731-6_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1021\/pr1008898","article-title":"Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain","volume":"10","author":"Liao","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1007\/s13311-019-00731-6_bib24","doi-asserted-by":"crossref","first-page":"34674","DOI":"10.1074\/jbc.M402324200","article-title":"Differential expression of cholesterol hydroxylases in Alzheimer's disease","volume":"279","author":"Brown","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/cne.21605","article-title":"Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain","volume":"507","author":"Ramirez","year":"2008","journal-title":"J Comp Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1146\/annurev.biochem.78.072407.103859","article-title":"Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain","volume":"78","author":"Russell","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1007\/s13311-019-00731-6_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068534","article-title":"Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain?","volume":"8","author":"Maioli","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00731-6_bib28","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","article-title":"Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice","volume":"289","author":"Mast","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuropharm.2017.06.026","article-title":"Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease","volume":"123","author":"Mast","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-019-00731-6_bib30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0022-2275(20)32393-2","article-title":"Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface","volume":"41","author":"Bretillon","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"10.1007\/s13311-019-00731-6_bib32","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1073\/pnas.0913828107","article-title":"ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD","volume":"107","author":"Bryleva","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev.biochem.66.1.613","article-title":"Acyl-coenzyme A:cholesterol acyltransferase","volume":"66","author":"Chang","year":"1997","journal-title":"Annu Rev Biochem"},{"key":"10.1007\/s13311-019-00731-6_bib34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M800584-JLR200","article-title":"LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins","volume":"50","author":"Hirsch-Reinshagen","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-2275(20)32052-6","article-title":"Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients","volume":"41","author":"Lutjohann","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-3940(00)01466-X","article-title":"Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases","volume":"293","author":"Bretillon","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neulet.2004.07.031","article-title":"Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients","volume":"368","author":"Kolsch","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1194\/jlr.M300320-JLR200","article-title":"Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease","volume":"45","author":"Heverin","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(01)02277-7","article-title":"On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells","volume":"314","author":"Bogdanovic","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neulet.2016.03.048","article-title":"The association between CYP46A1 rs4900442 polymorphism and the risk of Alzheimer's disease: A meta-analysis","volume":"620","author":"Jia","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/00207454.2012.751533","article-title":"Association of CYP46 gene polymorphism with sporadic Alzheimer's disease in Chinese Han populations: a meta-analysis","volume":"123","author":"Jin","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2013.06.011","article-title":"CYP46A1 intron-2T\/C polymorphism and Alzheimer's disease: an updated meta-analysis of 16 studies including 3,960 cases and 3,828 controls","volume":"549","author":"Li","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0005-2736(03)00025-7","article-title":"Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease","volume":"1610","author":"Gibson Wood","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-019-00731-6_bib44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.15252\/embr.201439225","article-title":"Cholesterol in brain disease: sometimes determinant and frequently implicated","volume":"15","author":"Martin","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1007\/s13311-019-00731-6_bib45","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1749-6632.1997.tb48466.x","article-title":"Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease?","volume":"826","author":"Sparks","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-019-00731-6_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000017234","article-title":"Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease","volume":"11","author":"Eckert","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1007\/s13311-019-00731-6_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1471-4159.2004.02849.x","article-title":"Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains","volume":"92","author":"Molander-Melin","year":"2005","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-019-00731-6_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neurobiolaging.2005.10.018","article-title":"Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex","volume":"28","author":"Gylys","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-019-00731-6_bib49","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/jnen\/60.8.778","article-title":"Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice","volume":"60","author":"Mori","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib50","doi-asserted-by":"crossref","first-page":"11080","DOI":"10.1021\/bi026173d","article-title":"Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease","volume":"41","author":"Roher","year":"2002","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-019-00731-6_bib51","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1007\/s13311-019-00731-6_bib52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ana.410340527","article-title":"The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease","volume":"34","author":"Mayeux","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0694-180","article-title":"Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease","volume":"7","author":"Corder","year":"1994","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-019-00731-6_bib54","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-019-00731-6_bib55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1007\/s13311-019-00731-6_bib56","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","article-title":"Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism","volume":"36","author":"Mahley","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1007\/s13311-019-00731-6_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrn2620","article-title":"Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy","volume":"10","author":"Bu","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-019-00731-6_bib59","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib60","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/brain\/awn212","article-title":"Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease","volume":"131","author":"Leoni","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-019-00731-6_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neulet.2011.03.025","article-title":"Whole body cholesterol metabolism is impaired in Huntington's disease","volume":"494","author":"Leoni","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","article-title":"Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression","volume":"55","author":"Leoni","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-019-00731-6_bib63","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awv384","article-title":"CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease","volume":"139","author":"Boussicault","year":"2016","journal-title":"Brain"},{"key":"10.1007\/s13311-019-00731-6_bib64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/nan.12286","article-title":"Evidence for altered cholesterol metabolism in Huntington's disease post mortem brain tissue","volume":"42","author":"Kreilaus","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1007\/s13311-019-00731-6_bib65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1471-4159.2010.06912.x","article-title":"Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease","volume":"115","author":"del Toro","year":"2010","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-019-00731-6_bib66","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","article-title":"Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease","volume":"25","author":"Valenza","year":"2005","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuron.2006.09.026","article-title":"Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery","volume":"52","author":"Lee","year":"2006","journal-title":"Neuron"},{"key":"10.1007\/s13311-019-00731-6_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neulet.2013.09.003","article-title":"Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease","volume":"555","author":"Bjorkhem","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib69","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.27609","article-title":"Brain cholesterol metabolism and Parkinson's disease.","volume":"34","author":"Huang","year":"2019","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-019-00731-6_bib70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2018.02.041","article-title":"The level of 24-hydroxycholesteryl esters decreases in plasma of patients with Parkinson's disease","volume":"672","author":"Di Natale","year":"2018","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00731-6_bib71","doi-asserted-by":"crossref","first-page":"e17299","DOI":"10.1371\/journal.pone.0017299","article-title":"Lipid pathway alterations in Parkinson's disease primary visual cortex","volume":"6","author":"Cheng","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00731-6_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease","volume":"5","author":"Wolozin","year":"2007","journal-title":"BMC Med"},{"key":"10.1007\/s13311-019-00731-6_bib73","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/mds.27413","article-title":"Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study","volume":"33","author":"Rozani","year":"2018","journal-title":"Movement Disorders"},{"key":"10.1007\/s13311-019-00731-6_bib74","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","article-title":"Statin use and the risk of Parkinson disease","volume":"70","author":"Wahner","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-019-00731-6_bib75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00415-012-6606-3","article-title":"Statin use and risk of Parkinson's disease: a meta-analysis of observational studies","volume":"260","author":"Undela","year":"2013","journal-title":"J Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib76","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/aje\/kwj283","article-title":"Serum cholesterol levels and the risk of Parkinson's disease","volume":"164","author":"de Lau","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1007\/s13311-019-00731-6_bib77","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.wnl.0000271883.45010.8a","article-title":"Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease","volume":"69","author":"Simon","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-019-00731-6_bib78","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.22013","article-title":"Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study","volume":"23","author":"Huang","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-019-00731-6_bib79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","article-title":"LXRS and FXR: the yin and yang of cholesterol and fat metabolism","volume":"68","author":"Kalaany","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"10.1007\/s13311-019-00731-6_bib80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nri1748","article-title":"Combinatorial roles of nuclear receptors in inflammation and immunity","volume":"6","author":"Glass","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-019-00731-6_bib81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-019-00731-6_bib82","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tem.2016.03.018","article-title":"LXR Regulation of Brain Cholesterol: From Development to Disease","volume":"27","author":"Courtney","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1007\/s13311-019-00731-6_bib83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2796.2011.02389.x","article-title":"Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo","volume":"270","author":"Shafaati","year":"2011","journal-title":"J Intern Med"},{"key":"10.1007\/s13311-019-00731-6_bib84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jcb.21006","article-title":"Nuclear localization of liver X receptor alpha and beta is differentially regulated","volume":"100","author":"Prufer","year":"2007","journal-title":"J Cell Biochem"},{"key":"10.1007\/s13311-019-00731-6_bib85","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1172\/JCI66533","article-title":"LXRbeta\/estrogen receptor-alpha signaling in lipid rafts preserves endothelial integrity","volume":"123","author":"Ishikawa","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-019-00731-6_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2012.06.051","article-title":"The NMDA receptor as a target for cognitive enhancement","volume":"64","author":"Collingridge","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-019-00731-6_bib87","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","article-title":"The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors","volume":"33","author":"Paul","year":"2013","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib88","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1152\/jn.00890.2015","article-title":"Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices","volume":"115","author":"Sun","year":"2016","journal-title":"J Neurophysiol"},{"key":"10.1007\/s13311-019-00731-6_bib89","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.12.028","article-title":"Preferential enhancement of GluN2B-containing native NMDA receptors by the endogenous modulator 24S-hydroxycholesterol in hippocampal neurons","volume":"148","author":"Wei","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-019-00731-6_bib90","doi-asserted-by":"crossref","first-page":"e03581","DOI":"10.7554\/eLife.03581","article-title":"GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine","volume":"3","author":"Miller","year":"2014","journal-title":"Elife"},{"key":"10.1007\/s13311-019-00731-6_bib91","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","article-title":"Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses","volume":"30","author":"Xia","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"10.1007\/s13311-019-00731-6_bib93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1073858414568122","article-title":"24(S)-Hydroxycholesterol as a modulator of neuronal signaling and survival","volume":"22","author":"Sun","year":"2016","journal-title":"Neuroscientist"},{"key":"10.1007\/s13311-019-00731-6_bib94","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/emboj.2012.31","article-title":"Cholesterol loss during glutamate-mediated excitotoxicity","volume":"31","author":"Sodero","year":"2012","journal-title":"EMBO J"},{"key":"10.1007\/s13311-019-00731-6_bib95","doi-asserted-by":"crossref","first-page":"12934","DOI":"10.1074\/jbc.M117.794909","article-title":"In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.","volume":"292","author":"Mast","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib96","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrm.2017.16","article-title":"The mystery of membrane organization: composition, regulation and roles of lipid rafts","volume":"18","author":"Sezgin","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-019-00731-6_bib97","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbamem.2015.03.029","article-title":"The influence of cholesterol on membrane protein structure, function, and dynamics studied by molecular dynamics simulations","volume":"1848","author":"Grouleff","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-019-00731-6_bib98","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.294.5545.1354","article-title":"CNS synaptogenesis promoted by glia-derived cholesterol","volume":"294","author":"Mauch","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-019-00731-6_bib99","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1096\/fj.00-0815fje","article-title":"Essential role for cholesterol in synaptic plasticity and neuronal degeneration","volume":"15","author":"Koudinov","year":"2001","journal-title":"Faseb J"},{"key":"10.1007\/s13311-019-00731-6_bib100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.expneurol.2008.04.019","article-title":"Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus","volume":"212","author":"Frank","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-019-00731-6_bib101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2012.06.053","article-title":"Lipid rafts, synaptic transmission and plasticity: impact in age-related neurodegenerative diseases","volume":"64","author":"Sebastiao","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-019-00731-6_bib102","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1113\/JP270590","article-title":"Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function","volume":"594","author":"Egawa","year":"2016","journal-title":"J Physiol"},{"key":"10.1007\/s13311-019-00731-6_bib103","doi-asserted-by":"crossref","first-page":"e0187168","DOI":"10.1371\/journal.pone.0187168","article-title":"Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1)","volume":"12","author":"Mast","year":"2017","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00731-6_bib104","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1073\/pnas.0600316103","article-title":"Brain cholesterol turnover required for geranylgeraniol production and learning in mice","volume":"103","author":"Kotti","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib105","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1074\/jbc.M505179200","article-title":"Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes","volume":"281","author":"Ohyama","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bbrc.2008.11.103","article-title":"Transcriptional regulation of cholesterol 24-hydroxylase by histone deacetylase inhibitors","volume":"378","author":"Shafaati","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-019-00731-6_bib107","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3233\/JAD-2010-100651","article-title":"Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination","volume":"22","author":"Milagre","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-019-00731-6_bib108","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1471-4159.2010.06612.x","article-title":"Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription","volume":"113","author":"Nunes","year":"2010","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-019-00731-6_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2008.05442.x","article-title":"Transcriptional regulation of the human CYP46A1 brain-specific expression by Sp transcription factors","volume":"106","author":"Milagre","year":"2008","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-019-00731-6_bib110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1471-4159.2011.07577.x","article-title":"Neuronal differentiation alters the ratio of Sp transcription factors recruited to the CYP46A1 promoter","volume":"120","author":"Milagre","year":"2012","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-019-00731-6_bib111","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1093\/hmg\/ddv268","article-title":"Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology","volume":"24","author":"Burlot","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-019-00731-6_bib112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/mt.2009.175","article-title":"Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease","volume":"18","author":"Hudry","year":"2010","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-019-00731-6_bib113","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.pharep.2017.04.018","article-title":"Possible anti-depressant effect of efavirenz and pro-depressive-like effect of voriconazole in specified doses in various experimental models of depression in mice","volume":"69","author":"Patel","year":"2017","journal-title":"Pharmacol Rep"},{"key":"10.1007\/s13311-019-00731-6_bib114","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/brain\/awv166","article-title":"CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease","volume":"138","author":"Djelti","year":"2015","journal-title":"Brain"},{"key":"10.1007\/s13311-019-00731-6_bib115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/ejn.12911","article-title":"Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus","volume":"41","author":"Chali","year":"2015","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib116","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1194\/jlr.M900174-JLR200","article-title":"The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase (CYP46A1) in vitro and in vivo","volume":"51","author":"Shafaati","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-019-00731-6_bib117","doi-asserted-by":"crossref","first-page":"e95500","DOI":"10.1371\/journal.pone.0095500","article-title":"Efavirenz promotes beta-secretase expression and increased Abeta1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND)","volume":"9","author":"Brown","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00731-6_bib118","doi-asserted-by":"crossref","first-page":"11394","DOI":"10.1073\/pnas.0805556105","article-title":"Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation","volume":"105","author":"Kotti","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib119","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1073\/pnas.0813349106","article-title":"Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan","volume":"106","author":"Halford","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib120","doi-asserted-by":"crossref","first-page":"14284","DOI":"10.1021\/bi035512f","article-title":"Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain","volume":"42","author":"Mast","year":"2003","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-019-00731-6_bib121","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0803717105","article-title":"Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain","volume":"105","author":"Mast","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00731-6_bib122","doi-asserted-by":"crossref","first-page":"31783","DOI":"10.1074\/jbc.M110.143313","article-title":"Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain","volume":"285","author":"Mast","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib123","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/mol.112.080424","article-title":"In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine","volume":"82","author":"Mast","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-019-00731-6_bib124","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1074\/jbc.M112.438754","article-title":"Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response","volume":"288","author":"Mast","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/mol.113.085902","article-title":"Antifungal azoles: structural insights into undesired tight binding to cholesterol-metabolizing CYP46A1","volume":"84","author":"Mast","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-019-00731-6_bib126","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1074\/jbc.M116.723577","article-title":"Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity","volume":"291","author":"Anderson","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00731-6_bib127","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: what we already know and questions that need to be answered.","volume":"70","author":"Apostolova","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s13311-019-00731-6_bib128","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-019-00731-6_bib129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.stem.2018.12.013","article-title":"Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-beta in iPSC-Derived Alzheimer's Disease Neurons","volume":"24","author":"van der Kant","year":"2019","journal-title":"Cell Stem Cell"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00731-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00731-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301810X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301810X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00731-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:12:54Z","timestamp":1761808374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301810X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S187874792301810X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00731-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00731-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}